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The use of tar and ultraviolet light as an inpatient 
therapy for psoriasis was described by Goeckerman 
more than 50 yr ago. Since that time it has been shown . 
to be an effective treatment for psoriasis at numerous 
medical centers with the average period of hospitaliza-
tion approximating 3 weeks. This study was designed to 
evaluate whether inpatient treatment would be com-
prised ifthe patients were permitted to spend each night 
of the final week of treatment at home. 
Of 267 patients hospitalized in 1979 for Goeckerman 
therapy, 84 patients were selected for study. These were 
divided into two groups, A and B. Group A consisted of 
patients receiving 3 weeks of inpatient care. Group B 
consisted of patients receiving 2 weeks hospitalization 
for inpatient Goeckerman therapy and 1 week of daily 
Goeckerman therapy in the ambulatory Psoriasis Treat-
ment Center while spending the previous evening at 
home. 
Group ' A and group B were compared for rate a nd 
degree of improvement and for duration of remission 
following hospital discharge. For purposes of statistical 
comparisons, patients from groups A and B were 
matched by sex, age, and date of admission to the study. 
Both groups showed 80-90% c learing in the first 3 
weeks. For patients in group A, the average total radia-
tion received was 61.3 J/sq cm ofUVA and 9.85 J/sq cm 
of UVB. The average total radiation received by group 
B was 61.3 J/sq cm of UVA and 8.63 J/sq cm of UVB. 
Neither difference was statistically s ignificant (p < 0.50). 
Both Group A and group B had similar numbers of 
patients who exacerbations required readmission to the 
hospital for either repeat Goeckerman therapy or for 
other types of treatment during the 18 mo follow-up 
period. The length of time before rehospitalization was 
also similar for both groups. 
These findings are of a preliminary nature. However, 
it appears that the rate of clearing and period without 
exacerbation in psoriasis can be maintained by modify-
ing the traditional inpatient Goeckerman regimen. 
Fifty-five years ago Goeckerman reported the therapeutic 
benefits of tar and ultraviolet light for the treatment of psoriasis. 
These original cases were all patients hospitalized at the Mayo 
Clinic [1]. The regimen consisted of (1) t\1e application of crude 
coal tal' (CCT) * for 24 hI', (2) the nonvigorous removal of tar 
·with olive oil, (3) irradiation of the lesions with a hot quartz 
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mercury vapor lamp emitting a discontinuous spectra of UV A 
and UVB radiation, and (4) a therapeutic bath containing 
"oatmeal and soda, or soap and water". Goeckerman also stated 
neither tar alone, nor UVL used independently produced bene-
fit "comparable to the combined use of the 2 agents" [1]. 
In 1968 Perry, Soderstrom, and Schulze [2] reviewed the 
Mayo Clinic's 40 yr of experience with Goeckerman's regimen 
in terms of patient satisfaction, extent of involvement, clinical 
improvement, and length of hospital stay. 
Today, controversy still exists as to the relative importance 
of the various components of the Goeckerman therapy; the 
most effective wavelengths of ultraviolet light and the ideal tar 
preparation continue to be debated [3-17]. However, there is 
widespread concensus concerning the efficacy of Goeckerman's 
hospital program [2,6,9,10,14,16,18,19-22]. 
In part because of this controversy, a long-term, prospective 
study has been undertaken to follow the course of 280 patients 
admitted to the Columbia-Presbyterian Medical Center in 1979. 
Particu lar emphasis was placed on evaluating the clincial re-
sponse of their psoriasis to the 3 modifications: (1) a more 
esthetic tar preparation, (2) the use of quantitative amounts of 
ultraviolet radiation type A and B based on the patient's skin 
type and (3) the reduction of hospital stay by administering the 
final portion of t he Goeckennan therapy in an ambulatory day 
care center designed to provide hospital level care. 
MATERIALS AND METHODS 
The patients in this study were chosen from those with severe plaque 
type psoriasis who were hospitalized at the Presbyterian Hospital 
between 1/1/ 79 and 12/31/ 79. The Goeckerman therapy used at th e 
Mayo Clinic in 1968, as described by Perry, Soderstrom,and Schulze 
[2], was taken as the standard. Assessments were made concerning the 
rate of clinical "clearing," the length of hospital stay, and the duration 
of clinical remission. In addition, similar assessments were made of a 
subset of patients in a prospective, pilot study undertaken in coopera-
tion with the New York and New Jersey Blue Cross Associations. This 
study is designed to evaluate the rate and extent of progress of patients 
who spent at least one-third of theil' treatment period in an ambu latol'y 
psoriasis treatment center. 
PATIENTS 
280 psoriatic patients were admitted to the Presbyterian 
Hospital during this 12-mo study period. T hirteen patients had 
previously responded poorly to, or did not tolerate, the Goeck-
erman therapy. T hey were treated with methotrexate (6 pa-
tients), pSOTalen and ultraviolet light (4 patients), or topical 
corticosteroids under occlusion (3 patients). These 13 patients 
have not been included in the following analysis. 
The remaining 267 patients (Table I) received an average of 
20 daily treatments. However, only 148 of these 267 patients 
were eligible for t he ambulatory psoriasis treatment center· 
• Goeckerman's Coal Tal' Ointment 
Crude Coal Tar 2-6 cc 
Zinc Oxide 30.00 
Petrolatum qs ad 120.00 
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TABLE 1. Age and sex o[ 267 patients hospitalized in 1979 [or 
Goecllel'lnan therapy at the Presby terian Hospital 
Age Male Female 
0-19 8 9 
20-29 17 31 
30-39 28 23 
40-49 23 9 
50-59 28 25 
fiO-69 30 21 
>70 9 6 
Total 143 124 
because it was only their primary insura nce provider who was 
participating in t his program. Eligible patients were divided 
into 2 groups designated group A a nd group B, in order to 
compare clinical progress. 
Group A-These patients received 3 weeks hospitalization 
for inpatient Goeckerman therapy. 
Group B-These patients received 2 weeks hospitalization 
for inpatient Goeckerma n t herapy a nd 1 week of 
da ily Goeckerma n therapy in th e a mbulato ry P so-
riasis Treatment Cen ter while spending the eve-
ning at home. 
Grou p A a nd gr oup B were compared for rate a nd degree of 
improvemen t a nd for dmat ion of remission following hospi tal 
discharge. For pmposes of statistical compru'isons, patients from 
groups A a nd B were matched by sex, age, (within 5 yr) , a nd 
date of admission to t he study (within 1 m ol. Eighty-fom 
patients wer e ascertained who could be matched by th ese 
cri tel"ia (see Table II).t They were divided into 42 matched 
pairs a nd evaluated for t he length of stay required fo r "clear-
ing." The matched pair varia bles were designed to avoid errors 
arising fi'om differences in age, sex, a nd season of therapy. 
Therapy sch edu les for both groups were s imilar a nd shown in 
Table III a nd IV. 
Light Source 
Treatm e nt dming the inpa tient phase was d elivered fi'om 
specially designed phototherapy uni ts co ntaining fluorescent 
UV A and UVB tubes arranged to completely surround th e 
patient. The phototherapy uni t (Houva -Lite UVA/ UVB Unit, 
Nationa l Biologics, Clevela nd, OH) used in t he hospital con-
tained 32 UVA tubes (Houva-Lite S72T12 BL-HO) a nd 16 UVB 
tubes (HO-B-FS72-TI2B). The ligh t sOW'ce used for patients 
who received photother apy in th e a mbulatory psoriasis t reat-
ment center (UV 8000 cabinet, Waldma nn Gmbh & Co., 
Schwenninge n, W . German y) co ntained 13 UVA tubes (Syl-
vania FR90TI2-HO PUV A) a nd 27 UVB tubes (Sylvania F75/ 
85-w UV-21) . The UVB flu orescent t ubes emi tted radiation 
prirnru'ily in t he 285-350 nm range and UV A tubes emitted 
radiation of 320-420 nm (Fig. 1) . UVA irradia nce was measured 
daily with a n International Light IL400 Reseru'ch R adiometer 
using a calibrated SEE 400 detector (half-power points 270-540 
run). UVB irradiance was measured m onthly using t he same 
radiome ter a nd a UVB fIl ter (half-power points 275- 303 nm). 
To determine the total UVB (280-320 nm) ra dia tion, t he spec-
tral sensitivity of the detector , a nd the emission spectrum of 
the UVB fluorescent tubes were correlated for compa rison with 
other standaJ"dized tubes. All measurements were ma de with 
the sensor fas tened in the center of a n empty cabinet 50 em 
from a wall of bulbs to which it was directed . Exposme time 
based on il"radia nce was calculated daily. 
t Of these, it was possible to collect data on 42 pairs for 6 mo, 36 
pairs fo r 12 mo and 5 pairs for 18 mo. Data sought was the length of 
time for readmission for hospital treatment of psoriasis and the t ime at 
which exacerbation of the psoriasis was noted. All statistical compari-
sons b etween the 2 groups incorporated the matched pairing of patients. 
Differences between means were tested by the paired-sample t-test; 
differences between proportions were tested by an exact b"inomial test. 
TABLE II. Age and .sex o[ 84 patients selected [or matched pairs 
Hospita l (group A) APTC" (group B) 
Age 
Male Female Ma le Female 
0-19 1 1 
20-29 1 6 4 6 
30-39 5 4 3 4 
40-49 6 2 7 3 
50-59 7 7 5 5 
60-69 1 1 2 2 
Tota l 21 21 21 21 
" APTC = ambula tory Psoriasis Treatment Center. 
TABLE Ill. Phototherapy schedule based on shin type 
1. Never tan, always burn 
II. Always burn, but 
sometimes tan 
III. Sometimes burn, bu t 
always Lan 
IV. Never burn, always tan 
V". Moderately pigmented 
VI". Blacks 
Initial Dose Daily Increment (J/ 
(J / sq em) sq cm ) 
UVA UVB UVA 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
.015 0.1-0.2 
.015 0.1-0.2 
.030 0.2-0.5 
.030 0.2-0.5 
.045 0.5-1.0 
.045 0.5-1.0 
UVB 
.Dl-.02 
.01-.02 
.02-.04 
.02-.04 
.04-.06 
.04-.06 
" Patients wi th natural pigmentation of these types should be clas-
sified in to lower skin type category if the sunburning history so indi-
cates. 
TABLE IV. Goecherman trea tment schedule" 
Therapeutic bath 
Topical application of tar 
and emollients 
PhoLotherapy 
Reapplication of emol-
lients 
Additional phototherapy 
Reapplication of emol-
lients 
Group A 
9:30-10:15 AM 
10:15-11:00 AM 
11:00-12:00 N 
2:00-3:00 PM 
3:00-5:00 PM 
6:30-7:30 PM 
Group B 
9:15-9:45 AM 
9:45-10: 15 PM 
]] :30-12:30 N 
12:30-1:30 PM 
8:00-9:00 (as 
needed) 
" Out patients arrive at 8:30-9:00 AM and leave at 4:30-5:30 PM: both 
groups are examined, receive. calp treatments and individual instruc-
tions (group A) or conferences (group B) da ily. 
Topical Medications 
The topical preparations used were compru'able for both 
group A a nd group B. T he use of topical corticosteroids was 
minimized exoept for lesions involving th e scalp , face, a nd 
in te rtriginous ar eas. Patients were instructed in t he proper 
application of medications required for t he Goeckerma n regi-
men a nd complia nce was monitored by nursing personnel. 
T he tar preparation used was a hydro-alcoholic gel (Estru' 
gel) conta ining a crude coal tru' extract rather t ha n 5% crude 
coal tar ointment to t he body twice daily. A major reason for 
this m odification was t hat it was found to be m or e accepta ble 
esthetical.ly th a n crude coal tru' for use by patients after hospi-
talization. Tar was not used on the fa ce or intertriginous ru·eas. 
Bla nd em ollients were applied as freque ntly as needed to relieve 
dl"yness. Each patient spent 20 min in a tepid bath containing 
a tar and oil mixture (Balnatal' and Alpha K eri Bath Oil). A 
superfatted soap was used wh en needed . In m any cases the 
patients received a second tar bath in t he afternoon. Salicylic 
acid ointments were only used early in the course of t herapy 
and discont inued when thick scales were removed. 
Phototherapy Schedules 
The skin type was used to determine each patient's ini tial 
a nd increm en tal phototherapy dosage of UVB a nd UV A (Table 
III) . Each patient was classified into skin types based on many 
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FIG 1. Goeckerman treatment schedule. 
of the criteria developed in th e cooperative trials of PUV A 
(psoralen and UV A therapy) [23]. 
Phototherapy was administered 7 days each week. The daily 
dose of ultraviolet A and ultraviolet B were designed to elicit a 
non tender erythema of uninvolved skin. When tenderness and 
eryth ema occurred, phototherapy was deferred until the tender-
ness and erythema had abated. Identical phototherapy sch ed-
ules were used for group A and group B . 
Clinical Severity and Response 
The severity of each patient's psoriasis was described by 
estimating the percentage of body sUlface involved as well as 
the morphology of the lesions (Table V) ."Clearing" was consid-
ered the goal of therapy and was defined as the stage when 
more than 80% of th e initial lesions h ad no induration, scale, or 
erythema. These criteria applied to all of th e patients who were 
included in the study. Scalp lesions were excluded from the 
evalua tion of "clearing." Exacerbation was defined as the re-
currence of more than 25% of lesions excluding those of th e 
scalp. Observations and treatments were recorded on a standard 
flow sh eet. An attempt was made to examine or contact all 
patients 1, 3, 6, 8, 10, 12 and 18 mo following discharge as 
"cleared." 
, 
RESULTS 
The average length of h ospitalization for all 267 patients 
admitted to the Presbyterian Hospital during 1979 for Goeck-
erman therapy using the tar gel and ultraviolet A + B was 20.0 
days. The data for male patients was 19.6 days (range 4-40) 
and for female patients was 20.3 days (range 3- 36). Comparison 
of the matched pai.rs of gro.up A and group B as indicated in 
Table VI showed the average length of hospitalization for both 
groups was not significantly different. Average total radiation 
received by patients of each skin type is noted in Table VII. All 
matched pairs were clear, as previously defined, at th e time of 
discharge. For patients in group A, the average total radiation 
received was 61.3 J /sq. cm of UVA and 9.85 J /sq. cm of UVB . 
. The average total radiation received by group B was 61.3 J /sq. 
cm of UVA and 8.63 J /sq. cm of UVB. Neither difference was 
statistica lly significant (p > 0.50). 
As note<:i in Fig 2 and 3, both group A and group B h ad a 
similar number of patients whose exacerbations required read-
mission to the hospital fo r either repeat Goeckerman th erapy 
or other types of treatment during the 18 rna follow-up period. 
The length of time before r eh ospitalization was also similar for 
both groups. 
The efficacy of the treatment received by group A and group 
B was also studied in terms of th e time of "clearing" to the 
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TABLE V. Key used to evaluate extent and severity of psoriasis 
Extent of lesions" 
A = 0 to 5% 
B = 5 to 25% 
C = 25 to 50% 
D = 50 to 75% 
E = Over 75% 
Severity of lesions 
o = No psoriasis 
1 = Red lesions, fl at 
2 = Red lesions, elevated , no scale 
3 = Red lesions, elevated, scale 
present 
4 = Erythroderma 
.. Expressed as percent of total body surface involved. 
TABLE VI. Length of hospitalization for 42 matched pairs in NY 
and NJ Blue Cross APTC study 
42 Pairs 
21 Male pairs 
21 Female pa irs 
Ave rage length of hospitalization (days) 
APTC" 
22.7 (18-34 ) 
22.2 (20-25) 
23. 1 (18-34) 
Hospita l 
22.4 (15-45) 
21.8 (15-26) 
22.9 (15-45) 
.. APTC = ambulato ry Psoriasis Treatment Center. 
TABLE VII. Average cumulative dosage of radiation received by 
patients of differen.t shin types clearing with Goecherma.n therapy 
Skin type 
I 
II 
III 
IV 
V 
VI 
UVA 
cumulative dose 
J/sq em 
44.2 
67.0 
67.0 
79.8 
107.9 
135.8 
UVB 
cumulative dose 
J /sq cm 
5.22 
7.53 
9.72 
10.41 
19.13 
23.56 
Note: Some patients had r eceived Goeckerman therapy on an am-
bulatory basis before admission, and were therefore able to tolerate a 
higher dose of ultraviolet radiation. This accounts for cumu lative doses 
of ultrav iolet radiation being higher for some individuals within a given 
skin type than those starting at t he dose levels indicated in T able III. 
Cumula tive 
Pa tie nts 
Rehospitalized 
In Each Group 
30% 
4 
• GROUP A - INPATIENT 
o GROUP B - APTC 
40 
Weeks o f Follow·Up 
48 56 
FIG 2. Cumulative hospitalizations for 36 matched pail's N .Y. N .J . 
Blue Cross Ambulatory Psoriasis Treatment Center (APTC) Study. 
Patients with 
Exacerbation 
In Each Group 
25% 
4 8 
• GROUP A -INPATIENT 
o GROUP B-APTC 
12 24 32 40 48 
Length of Time Irom Hospital Discharge (weeks) 
FIG 3. Comparison of t he times of exacerbation of psoriasis for 36 
matched pairs in N.Y. N.J. Blue Cross Ambulatory P soriasis Treatment 
Center (APTC) Study. 
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time of exacerbation. This was determined by either the phy-
sician's evaluation that the psoriasis was worsening or if nec-
essary by telephone contact. The 18 mo data concerning exac-
erbation indicate that the 2 groups are similar except for an 
apparently initial higher number of failures at 1 mo in group B. 
This difference, however, is not statistically significant (p > 
0.25). 
DISCUSSION 
Goeckerman first described the use of crude coal tar and 
ultraviolet light for the successful treatment of psoriasis 55 yl' 
ago. Its efficacy has been documented repeatedly in routine 
hospital care. However, there has been considerable debate 
concerning the relative therapeutic necessity and importance of 
tar as well as the type and amount of ultraviolet radiation 
(Table VII). It is only recently that quantitative dosimetry of 
the ultraviolet light administered [13,15] has been included in 
studies of Goeckerman therapy. Unfortunately evaluation of 
the length of remission obtained by any of these modifications 
of the Goeckerman regimen has rarely been reported [2,20]. 
Quantitative ultraviolet light dosimetry was used in compar-
ing the therapeutic response of patients in group A and group 
B. The ambulatory component of the hospital Goeckerman 
regimen was investigated and analyzed statistically using 
matched pairs. Its efficacy was found to be comparable to that 
for most patients who were hospitalized for 3 weeks (group A). 
Although paiTed comparisons of tar gel and crude tar oint-
ment were not pelformed in this study, the therapeutic data 
obtained with the tar gel correlated closely with that obtained 
by Perry, Soderstrom, and Schulze [2] using crude coal tar 
when assessed in terms of rate of improvement during the 
period of hospitalization and time required for clearing. The 
average hospitalization of 20 days in this study is strikingly 
similar to the findings reported at the Mayo Clinic 12 yr ago. 
Those patients who were in our study had greater than 25% of 
body surface involvement and obtained at least 80% clearing. 
In those patients described by Perry, Soderstrom, and Schulze 
with similar extent and resolution of psoriasis the average 
hospital stay was 19-21 days. Mac Kenna [19] in 1959 also 
reported an average length of hospital stay of 21 days for 
patients receiving crude coal tar for Goeckerman therapy. The 
similar dW'ation of hospitalization of these 3 studies also suggest 
that the effectiveness of the tar gel is comparable to crude tar 
ointments. In terms of treatment compliance, especiaUy for use 
at home, the tar gel is clearly preferred by patients. Other 
investigators have also found that tar gel is effective, but report 
that more phototherapy treatments are necessary for clearing 
than with crude tar ointment [11 ,14,15]' 
A major difficulty in comparing length of hospitalization in 
this study with other published series arises from ambiguity 
about the number of phototherapy treatments [14,16]. Days 
when treatments were deferred because of tenderness or ery-
thema were not recorded in most studies. 
Data concerning type and amount of total ultraviolet radia-
tion received is as relevant in determining actual effect of 
Goeckerman therapy as the number of phototherapy treat-
ments. With the increased use of dosimetry and standardization 
of meters becoming more prevalent, compaTisons of the thera-
peu tic results of different studies as well as the long-term effects 
of Goeckerman phototherapy will become more meaningful. 
However, until a standard technique and instrument for cali-
brating phototherapy units has been accepted, dosimetry will 
remain a problem [15]. In a recent study of modified Goecker-
man therapy suberythema doses were reported by Frost et al 
[15]. His schedule of UVB required 25-30 treatments for clear-
ing of most psoriatic lesions with a mean cumulative dose of 
UVE of 406 mJ/ sq cm, where daily erythema was not attained. 
However, direct comparison of these data with our results is 
not possible since different meters and ftlters were used. The 
minimal erythema dose from UVB reported by Frost was 6-25 
mJ /sq cm as compared to our value of 20-50mJ/sq cm in 
Caucasian patients. 
Parrish et al [13] recorded UVB MED's from UVB radiation 
as 20-45 mJ/ sq em, measuring the irradiance with a patient 
standing in the phototherapy unit. These minimal erythema 
doses were similar to ours, but our irradiance was measured 
with the sensor in an empty phototherapy unit. Using similar 
treatment schedules, Parrish's recorded cumulative UVB dose 
(657-3950 mJ / sq cm) is also less than ours. This may be 
explained by dosimetry studies that indicate 10-20% higher 
recorded levels of UVB when irradiance measurements are 
made in an empty chamber rather than with an enclosed patient 
who is absorbing photons. To date no ideal system is available 
that measures the amount of photons absorbed by the patient. 
By quantitating UVB exposure to UVB dosimetry allows 
comparison of one possible variable in the Goeckerman therapy. 
In this study, the insignificant difference in the 2 groups' 
cumulative doses of UVB eliminates total UVB exposure as a 
variable factor of the time and rate of progress in group A and 
group B. 
The amount of time that improvement is maintained follow-
ing "clearing" is an important consideration in assessing the 
value of that therapy. The endpoint of remission for anyone 
patient is determined both by the increase of the number and 
size of psoriatic lesions and the patient's impression that his 
disease has reached an unacceptable stage. Quantitating these 
clinical ftndings for comparison of the status of all patients is 
difficult and involved subjective factors. 
The use of matched pairs in this study permitted statistical 
comparison of 2 groups. It permitted the control of the major 
variables of patient populations related to: age, sex, and season 
of therapy thus assuring similarity of the groups. To the best of 
our knowledge this paper documents for the first time that the 
response of a group receiving part of the treatment on an 
ambulatory basis is not statistically different from the group 
treated entiTely in the hospital. Two parameters were followed 
for this comparison: (1) the length oftime until a n exacerbation 
of psoriasis was noted, a nd (2) the proportion of patients whose 
exacerbation was sufficient to require readmission. To date the 
course of patients in this matched pail' study is comparable for 
both groups using the two criteria individually 01' together. 
These preliminary data suggest that a portion of inpat ient 
Goeckerman therapy can be administered partially in an am-
bulatory care setting without altering the rate of improvement 
01' the time 'required for "cleaTing." 
European studies had first indicated the feasibility of this 
approach [25]. Cram and King [22,26] described the first day 
care center for psoriasis to the United States. His studies 
suggested an ambulatory center would be a less expensive 
method of treating psoriatic patients with hospital level care 
than would full inpatient hospitalization. The possibilities of 
using a total ambulatory care Goeckerman regimen needs to be 
further evaluated and compared to group A and group B. Our 
initial data suggests a significantly longer period of time is 
required for clearing and that the rate of improvement is slower 
in the program described by Cram. 
It is also important to have further controlled studies with 
lower doses of ultraviolet light, shorter periods of hospitalization 
and more esthetic topical tar preparations. Throughout all the 
proposed studies the goals should remain to increase the rate of 
clearing of psoriasis and decrease the hospital stay. A prolonged 
length of remission must also be sought. None of the 3 goals 
should be compromised for expediency. 
This report is not intended to be definitive, but rather to 
present the eal'ly findings of a prospective study of Goeckerman 
therapy. A. larger investigation of 75 matched pail's, each ob-
served for two yeal'S, is cWTently in progress. 
In summaTY, this study has shown the feasibility of using an 
esthetic tal' preparation and quantitative amounts of ultraviolet 
A and B (based on skin types) in the administration of a 
modified Goeckerman regimen. Matched pail' studies indicate 
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that patients receiving this type of therapy showed the same 
degree a nd rate of improvement and maintenance of clearing 
when the last third of hospital treatment was delivered in an 
ambulatory day care psoriasis center. 
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